Image pharmaphorum Editor R&D Heard on the pipeline: R&D in the pharma industry In the fast-paced world of healthcare, it can take a lot of work to keep up-to-date with the numerous innovations, trends, and opinions that emerge each year. R&D What’s next for oncology research? Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023. R&D Plotting the way forward on clinical trial diversity As the old adage goes, the first step towards solving a problem is admitting you have one. R&D Into the bowels of gut research For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge. Load more results
R&D Heard on the pipeline: R&D in the pharma industry In the fast-paced world of healthcare, it can take a lot of work to keep up-to-date with the numerous innovations, trends, and opinions that emerge each year.
R&D What’s next for oncology research? Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023.
R&D Plotting the way forward on clinical trial diversity As the old adage goes, the first step towards solving a problem is admitting you have one.
R&D Into the bowels of gut research For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge.
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
